Who's Liable For Online Content? Pharma, Marketers Disagree (Slightly)
Executive Summary
Compensation and collaboration - as well as creation - should be the triggers for determining a pharmaceutical company's liability for Internet content, Rohit Bhargava of Ogilvy 360 Digital Influence advised FDA during a Nov. 12-13 hearing on promoting medical products on the Internet and in social media
You may also be interested in...
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.
Pharma Social Media Sites Struggle For Audience Under Shadow Of Potential FDA Action
Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.
Internet-Focused Promotion, Warning Letters Both Up As FDA Guidance Nears
As pharmaceutical companies await FDA guidance to help them navigate the pitfalls of Internet and social media promotion, firms are steadily increasing their participation on the Internet in general.